Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795087 · ClinicalTrials.gov registry record
Discharge Medication Use Post-Operatively in GU Cancer Patients
A clinical trial of Genitourinary Cancer, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 684
- Enrollment target
- 1
- Study location
NCT06795087 is a study of Genitourinary Cancer that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 684 participants, below the 1,499-participant average among 12 other Genitourinary Cancer trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06795087, a study of Genitourinary Cancer, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 684 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this research study is to determine the amount of opioids that are taken after discharge following a cystectomy, nephrectomy (partial or total), or prostatectomy surgeries via a 30-day post- discharge opioid use and disposal survey. We will also evaluate the impact of an opioid disposal education pamphlet on proper disposal of unused opioids.
Conditions Studied
Interventions
- OTHER Opioid Medication Disposal Education
Study Locations (1)
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2027-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06795087
The ClinicalTrials.gov registry entry for NCT06795087 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 684 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,499-participant average among 12 other Genitourinary Cancer trials with a reported enrollment target (54% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Genitourinary Cancer appearing as the primary indexed condition, and to 1 intervention - of which Opioid Medication Disposal Education is the first listed.
NCT06795087 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06795087 about?
NCT06795087 is a clinical study titled "Discharge Medication Use Post-Operatively in GU Cancer Patients". The main purpose of this research study is to determine the amount of opioids that are taken after discharge following a cystectomy, nephrectomy (partial or total), or prostatectomy surgeries via a 30-day post- discharge opioid use and disposal survey. We will also evaluate the impact of an opioid d...
What is the current status of trial NCT06795087?
This trial is currently recruiting. The enrollment target is 684 participants. The study started on 2025-02-21. Estimated completion is 2027-07.
What conditions does trial NCT06795087 study?
This clinical trial studies the following conditions: Genitourinary Cancer.
What interventions are being tested in trial NCT06795087?
The interventions under investigation include: Opioid Medication Disposal Education (OTHER).
Who is sponsoring clinical trial NCT06795087?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06795087 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genitourinary Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
RECRUITING
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
RECRUITING
-
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
RECRUITING · Phase 1
-
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.